Starting just before the 22-minute mark of this presentation, as it relates to PGNX and Relistor, SLXP's CEO states that the current peak-year sales estimate for Relistor (she termed peak-year as being year 7) in its currently approved indication is about $50M. If they gain expanded approval in chronic patients, that peak estimate is $300-$350M. If SLXP/PGNX succeed in gaining approval for oral Relistor, that takes them to a "billion dollar opportunity."
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.